Alpha 2.0
Login Register
» Authors » Fred C Semitala

Fred C Semitala

Explore the profile of Fred C Semitala including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 81
Citations 567
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Health Services
Top 10 Co-Authors
Moses R Kamya
Adithya Cattamanchi
Christina Yoon
Anne R Katahoire
David W Dowdy
Martin Muddu
Moses Kamya
Joanita Nangendo
Jillian L Kadota
Fred Welishe
Published In
PLoS One
PLOS Glob Public Health
BMC Health Serv Res
Res Sq
Implement Sci Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Determinants of continuation on HIV pre-exposure propylaxis among female sex workers at a referral hospital in Uganda: a mixed methods study using COM-B model
Kawuma S, Katwesigye R, Walusaga H, Akatukunda P, Nangendo J, Kabugo C, et al.
BMC Public Health . 2025 Jan; 25(1):143. PMID: 39806342
Background: Female sex workers (FSWs) have the highest HIV prevalence in Uganda. Pre-exposure prophylaxis (PrEP) has been recommended as a key component of the HIV combination prevention strategy. Although patient...
2.
Provider assisted partner notification utilization and associated factors among adolescents living with HIV in Uganda, a cross-sectional study
Kinera-Kagimu I, Katuramu R, Nangendo J, Semitala F, Nabukeera-Barungi N, Dhabangi A
BMC Pediatr . 2024 Nov; 24(1):785. PMID: 39614228
Background: Assisted Partner Notification (APN) is a high yield HIV testing strategy that is recommended by the World Health Organization (WHO) for adults and adolescents aged at least 15 years...
3.
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment
Aschmann H, Musinguzi A, Kadota J, Namale C, Kakeeto J, Nakimuli J, et al.
J Int AIDS Soc . 2024 Nov; 27(12):e26390. PMID: 39587885
Introduction: Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens...
4.
Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda
Kadota J, Musinguzi A, Aschmann H, Akello L, Welishe F, Nakimuli J, et al.
Open Forum Infect Dis . 2024 Nov; 11(11):ofae667. PMID: 39582503
Background: Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high-TB-burden countries. Despite established safety and tolerability in efficacy trials, 3HP-related adverse...
5.
Prevalence, associated factors, barriers and facilitators for oral HIV self-testing among partners of pregnant women attending antenatal care clinics in Wakiso, Uganda
Nduhukyire L, Semitala F, Mutanda J, Muramuzi D, Ipola P, Owori B, et al.
AIDS Res Ther . 2024 Nov; 21(1):82. PMID: 39538315
Background: Oral HIV self-testing (HIVST) among men is relatively low and still inadequate in Sub-Saharan Africa. Delivering HIVST kits by pregnant women attending antenatal care to their partners is a...
6.
Isoniazid Preventive Therapy Adherence and Its Predictors Among Soldiers on HIV Antiretroviral Therapy at a General Military Hospital in Uganda
Moses S, Mupere E, Nangendo J, Semitala F, Kalyango J, Chemonges S, et al.
HIV AIDS (Auckl) . 2024 Nov; 16:413-421. PMID: 39524020
Background: Uganda faces a significant dual challenge with tuberculosis (TB), ranking among these countries most affected by the disease worldwide. The World Health Organization (WHO) recommends isoniazid preventive therapy (IPT)...
7.
Building locally anchored implementation science capacity: the case of the adolescent HIV implementation science alliance-supported local iS alliances
Vorkoper S, Agot K, Dow D, Mbizvo M, Mugo C, Sam-Agudu N, et al.
Front Health Serv . 2024 Oct; 4:1439957. PMID: 39469436
Background: The Fogarty International Center-led Adolescent HIV Implementation Science Alliance (AHISA) supports region-/country-specific implementation science (IS) alliances that build collaborations between research, policy, and program partners that respond to local...
8.
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial
Musinguzi A, Kasidi J, Kadota J, Welishe F, Nakitende A, Akello L, et al.
PLOS Glob Public Health . 2024 Oct; 4(10):e0003347. PMID: 39446746
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify...
9.
Current out of pocket care costs among HIV and hypertension co-morbid patients in urban and peri-urban Uganda
Cameron D, Morrell L, Kagoya F, Kiggundu J, Hutchinson B, Twine R, et al.
PLOS Glob Public Health . 2024 Sep; 4(9):e0003423. PMID: 39321165
Background: Despite improvements to the cascade of HIV care in East Africa, access to care for non-communicable disease co-morbidities like hypertension (HTN) remains a persistent problem. The integration of care...
10.
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial
Musinguzi A, Kasidi J, Kadota J, Welishe F, Nakitende A, Akello L, et al.
medRxiv . 2024 Sep; PMID: 39314926
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify...